DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase 2b clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase 1b clinical trial to treat patients with metabolic dysfunction-associated steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; PERSERIS an injectable suspension for the treatment of schizophrenia in adults; and Methydur to treat attention deficit hyperactivity disorder. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.